EMERGENT BIOSOLUTIONS INC. Cash and Cash Equivalents, Period Increase (Decrease)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$66.90 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-22
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$227.97M.
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $149.12M, a 487.92% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $26.63M, a 41.41% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$14.69M.
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$66.90M.
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$93.20M.
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$41.30M, a 227.88% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $32.30M, a 68.07% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2018-12-31 | -$227.97M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$78.84M derived: sum of 2 quarters · filed 2019-02-22 | -$52.21M derived: sum of 3 quarters · filed 2019-02-22 | -$66.90M 10-K · filed 2019-02-22 | ||
| 2018-09-30 | $149.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $175.75M derived: sum of 2 quarters · filed 2018-11-02 | $161.07M 10-Q · filed 2018-11-02 | -$1.61M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2018-06-30 | $26.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $11.95M 10-Q · filed 2018-08-03 | -$150.73M derived: sum of 3 quarters · filed 2019-02-22 | -$125.37M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2018-03-31 | -$14.69M 10-Q · filed 2018-05-04 | -$177.36M derived: sum of 2 quarters · filed 2019-02-22 | -$152.00M derived: sum of 3 quarters · filed 2019-02-22 | -$106.54M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-12-31 | -$162.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$137.31M derived: sum of 2 quarters · filed 2019-02-22 | -$91.86M derived: sum of 3 quarters · filed 2019-02-22 | -$93.20M 10-K · filed 2019-02-22 | -$93.22M 10-K · filed 2018-02-23 | |
| 2017-09-30 | $25.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $70.82M derived: sum of 2 quarters · filed 2018-11-02 | $69.48M 10-Q · filed 2018-11-02 | $42.04M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-06-30 | $45.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $44.11M 10-Q · filed 2018-08-03 | $16.68M derived: sum of 3 quarters · filed 2019-02-22 | -$17.79M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-03-31 | -$1.34M 10-Q · filed 2018-05-04 | -$28.78M derived: sum of 2 quarters · filed 2019-02-22 | -$63.24M derived: sum of 3 quarters · filed 2019-02-22 | -$70.86M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2016-12-31 | -$27.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$61.90M derived: sum of 2 quarters · filed 2019-02-22 | -$69.52M derived: sum of 3 quarters · filed 2019-02-22 | -$41.30M 10-K · filed 2019-02-22 | -$41.28M 10-K · filed 2017-02-28 | |
| 2016-09-30 | -$34.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$42.08M derived: sum of 2 quarters · filed 2017-11-03 | -$13.86M 10-Q · filed 2017-11-03 | -$9.79M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-06-30 | -$7.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $20.60M 10-Q · filed 2017-08-04 | $24.68M derived: sum of 3 quarters · filed 2018-02-23 | $118.55M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-03-31 | $28.22M 10-Q · filed 2017-05-05 | $28.22M 10-Q · filed 2016-05-06 | $32.30M derived: sum of 2 quarters · filed 2018-02-23 | $126.17M derived: sum of 3 quarters · filed 2018-02-23 | $124.50M derived: sum of 4 quarters · filed 2018-02-23 | |
| 2015-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $97.95M derived: sum of 2 quarters · filed 2018-02-23 | $96.28M derived: sum of 3 quarters · filed 2018-02-23 | $32.30M 10-K · filed 2018-02-23 | ||
| 2015-09-30 | $93.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $92.20M derived: sum of 2 quarters · filed 2016-11-09 | $28.22M 10-Q · filed 2016-11-09 | $66.47M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | -$1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$65.66M 10-Q · filed 2016-08-05 | -$27.41M derived: sum of 3 quarters · filed 2017-02-28 | $46.71M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | -$63.98M 10-Q · filed 2016-05-06 | -$25.73M derived: sum of 2 quarters · filed 2017-02-28 | $48.38M derived: sum of 3 quarters · filed 2017-02-28 | $56.30M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $38.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $112.37M derived: sum of 2 quarters · filed 2017-02-28 | $120.28M derived: sum of 3 quarters · filed 2017-02-28 | $101.16M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $74.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $82.03M derived: sum of 2 quarters · filed 2015-11-06 | $62.91M 10-Q · filed 2015-11-06 | $69.69M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $7.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$11.21M 10-Q · filed 2015-08-06 | -$4.43M derived: sum of 3 quarters · filed 2016-02-29 | $11.89M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | -$19.12M 10-Q · filed 2015-05-08 | -$12.35M derived: sum of 2 quarters · filed 2016-02-29 | $3.97M derived: sum of 3 quarters · filed 2016-02-29 | $29.98M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $23.09M derived: sum of 2 quarters · filed 2016-02-29 | $49.10M derived: sum of 3 quarters · filed 2016-02-29 | $37.67M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $16.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $42.32M derived: sum of 2 quarters · filed 2014-11-10 | $30.89M 10-Q · filed 2014-11-10 | -$25.34M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2013-06-30 | $26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $14.58M 10-Q · filed 2014-08-08 | -$41.66M derived: sum of 3 quarters · filed 2015-03-09 | -$5.60M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2013-03-31 | -$11.43M 10-Q · filed 2014-05-12 | -$67.66M derived: sum of 2 quarters · filed 2015-03-09 | -$31.61M derived: sum of 3 quarters · filed 2015-03-09 | -$20.19M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2012-12-31 | -$56.23M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | -$20.18M derived: sum of 2 quarters · filed 2015-03-09 | -$8.76M derived: sum of 3 quarters · filed 2015-03-09 | -$2.23M 10-K · filed 2015-03-09 | ||
| 2012-09-30 | $36.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $47.48M derived: sum of 2 quarters · filed 2013-11-08 | $54.00M 10-Q · filed 2013-11-08 | $72.56M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-06-30 | $11.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $17.94M 10-Q · filed 2013-08-06 | $36.50M derived: sum of 3 quarters · filed 2014-03-10 | $39.75M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-03-31 | $6.52M 10-Q · filed 2013-05-03 | $25.08M derived: sum of 2 quarters · filed 2014-03-10 | $28.33M derived: sum of 3 quarters · filed 2014-03-10 | $13.50M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2011-12-31 | $18.55M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $21.81M derived: sum of 2 quarters · filed 2014-03-10 | $6.98M derived: sum of 3 quarters · filed 2014-03-10 | -$25.12M 10-K · filed 2014-03-10 | ||
| 2011-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$11.58M derived: sum of 2 quarters · filed 2012-11-01 | -$43.67M 10-Q · filed 2012-11-01 | -$25.88M derived: sum of 4 quarters · filed 2013-03-08 | ||
| 2011-06-30 | -$14.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$46.92M 10-Q · filed 2012-08-03 | -$29.14M derived: sum of 3 quarters · filed 2013-03-08 | $19.90M derived: sum of 4 quarters · filed 2013-03-08 | ||
| 2011-03-31 | -$32.09M 10-Q · filed 2012-05-04 | -$14.30M derived: sum of 2 quarters · filed 2013-03-08 | $34.73M derived: sum of 3 quarters · filed 2013-03-08 | |||
| 2010-12-31 | $17.79M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $66.83M derived: sum of 2 quarters · filed 2013-03-08 | $66.09M 10-K · filed 2013-03-08 | |||
| 2010-09-30 | $49.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $48.30M 10-Q · filed 2011-11-04 | ||||
| 2010-06-30 | -$731.00K 10-Q · filed 2011-08-05 | |||||
| 2009-12-31 | $11.45M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |